ReviewCardiovascular diabetology2020
Issues for the management of people with diabetes and COVID-19 in ICU.
Review in Cardiovascular diabetology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Predictor factor for worse outcomes in kidney transplant recipients infected with coronavirus disease 2019: A systematic review and meta-analysis.Transplant immunology · 2023Pooled it
- The Association Between Dysglycemia and Endotheliopathy in ICU Patients With and Without Diabetes: A Cohort Study.Critical care explorations · 2025Observational
- Increased risk of poor clinical outcome in COVID-19 patients with diabetes mellitus and in-hospital mortality predictors: A retrospective cohort from a tertiary hospital in Indonesia.Endocrinology, diabetes & metabolism · 2023Article
- Article
- COVID-19 therapeutics: Clinical application of repurposed drugs and futuristic strategies for target-based drug discovery.Genes & diseases · 2023Review
- Stress Hyperglycemia Drives the Risk of Hospitalization for Chest Pain in Patients With Ischemia and Nonobstructive Coronary Arteries (INOCA).Diabetes care · 2023Article
- 16. Diabetes Care in the Hospital: Standards of Care in Diabetes-2023.Diabetes care · 2023Review
- Diabetes Research and Clinical Practice and the fight against COVID-19.Diabetes research and clinical practice · 2022Article
- Urban-Rural Differences in Health Care Utilization and COVID-19 Outcomes in Patients With Type 2 Diabetes.Preventing chronic disease · 2022Article
- Article
- Effect of Hyperglycemia on COVID-19 Outcomes: Vaccination Efficacy, Disease Severity, and Molecular Mechanisms.Journal of clinical medicine · 2022Review
- Recent Updates to Clinical Practice Guidelines for Diabetes Mellitus.Endocrinology and metabolism (Seoul, Korea) · 2022Review
- Potential therapeutic effect of glucagon-like peptide-1 receptor agonists on COVID-19-induced pulmonary arterial hypertension.Medical hypotheses · 2022Article
- The Role of Endothelium in COVID-19.International journal of molecular sciences · 2021Review
- The role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanism.Expert opinion on drug safety · 2021Review
- The role of T-cell immunity in COVID-19 severity amongst people living with type II diabetes.The FEBS journal · 2021Review
- Incretin-based therapies in 2021 - Current status and perspectives for the future.Metabolism: clinical and experimental · 2021Article
- Epicardial adipose tissue and severe Coronavirus Disease 19.Cardiovascular diabetology · 2021Article
- Pharmacological management of COVID-19 in type 2 diabetes.Journal of diabetes and its complications · 2021Review
- The management of patients with coronavirus disease 2019 in intensive care unit (ICU) in low income countries: A review article.Clinical nutrition open science · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 8 institutions in 8 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the pandemic "Corona Virus Disease 2019" (COVID-19) people with diabetes have a high risk to require ICU admission. The management of diabetes in Intensive Care Unit is always challenging, however, when diabetes is present in COVID-19 the situation seems even more complicated. An optimal glycemic control, avoiding acute hyperglycemia, hypoglycemia and glycemic variability may significantly improve the outcome. In this case, intravenous insulin infusion with continuous glucose monitoring should be the choice. No evidence suggests stopping angiotensin-converting-enzyme inhibitors, angiotensin-renin-blockers or statins, even it has been suggested that they may increase the expression of Angiotensin-Converting-Enzyme-2 (ACE2) receptor, which is used by "Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to penetrate into the cells. A real issue is the usefulness of several biomarkers, which have been suggested to be measured during the COVID-19. N-Terminal-pro-Brain Natriuretic-Peptide, D-dimer and hs-Troponin are often increased in diabetes. Their meaning in the case of diabetes and COVID-19 should be therefore very carefully evaluated. Even though we understand that in such a critical situation some of these requests are not so easy to implement, we believe that the best possible action to prevent a worse outcome is essential in any medical act.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.